26 November 2025
This report provides a synthesis of the outcomes of the first paediatric drug optimization exercise that was held for Malaria. The PADO for malaria meeting brought together academic researchers, clinical experts, implementing partners and other key stakeholders involved in research and development to reach consensus on the first ever PADO lists for malaria. These contain three key antimalarial agents to be developed in the short term (PADO priority list) and to be monitored in the longer term (PADO watch list), with a clear message on the need to continue investigating long-acting injectables, given their potential role in future malaria management. Additionally, the PADO-malaria access list will support all stakeholders to advocate for greater access to, uptake and roll out of the products included, through multiple activities.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.